AAVXF OTC
Credit Risk of going bust: lower than 81% of companies Debt: 0.0% of company value Bonds: none of note held by US funds details ▾
Total debt $1.3M against a stock market value of $7.62B.
Distance to default 9.87 (Merton model): prices to 2026-10-26, balance sheet 2026-06-30, debt counted $674K (short-term plus half of long-term), stock volatility 90.8%; Altman Z'' -2.56. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Paris, IF 75009
FR
Abivax S.A., a French biopharmaceutical firm, specializes in the discovery and enhancement of pharmaceutical treatments targeting inflammatory conditions, infectious illnesses, and various forms of cancer. The company's flagship compound, ABX464, is currently undergoing Phase IIb clinical evaluations for ulcerative colitis, Crohn's disease, and COVID-19. It is also being assessed in Phase IIa trials for rheumatoid arthritis, and has successfully concluded Phase IIa studies demonstrating viral remission in individuals with HIV. Additionally, Abivax is advancing ABX 196, an investigational immune-enhancing agent, through Phase 1/2 clinical trials for its potential application in treating hepatocellular carcinoma. Further research initiatives by the company explore therapies for Dengue fever, influenza, and respiratory syncytial virus. Abivax S.A. holds licensing agreements with prominent French research institutions, including the French National Centre for Scientific Research, the University of Montpellier, and the Institut Curie. Established in 2013, the company maintains its primary offices in Paris, France.